Results 251 to 260 of about 29,485 (291)
Some of the next articles are maybe not open access.
Bispecific antibodies for delivery into the brain
Current Opinion in Chemical Biology, 2013The blood-brain barrier (BBB) is a formidable obstacle preventing drug delivery to the brain, particularly for large protein therapeutics. The utilization of endogenous brain endothelial transport pathways, however, represents a promising approach to cross the cellular barrier through receptor-mediated transcytosis.
Ryan J, Watts, Mark S, Dennis
openaire +2 more sources
Chemical Production of Bispecific Antibodies
2004This chapter discusses two related methods for creating Fab' x Fab' chemically linked BsAb. Both methods require the generation of purified F(ab')2 fragments of each antibody and use reagents that react with the free thiols generated upon reduction of interheavy chain disulfide bonds of the F(ab')2 fragments. Upon reduction, the resulting Fabs are then
Robert F, Graziano, Paul, Guptill
openaire +2 more sources
Bispecific antibodies in oncology
Nature Reviews Drug Discovery, 2022Arman, Esfandiari +2 more
openaire +2 more sources
Bispecific antibody therapy for lymphoma
Best Practice & Research Clinical HaematologyThe rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL.
Genevieve M, Gerhard +1 more
openaire +2 more sources
Immunotherapeutic potential of bispecific antibodies
Immunology Today, 1997Abstract Bispecific antibodies (BsAbs) offer therapeutic potential by targeting tumors or pathogens as well as cytotoxic effector and/or antigen-presenting cells. A recent meeting ∗ ∗The Vth World Conference on Bispecific Antibodies was held at Volendam, The Netherlands, on 25–28 June 1997. focused on current issues in the BsAb field.
J G, van de Winkel +2 more
openaire +2 more sources
Strategies for the Generation of Bispecific Antibodies
ChemBioChemBispecific antibodies (BsAbs) are engineered immunoglobulins that can simultaneously recognize two distinct antigens or two distinct epitopes on the same antigen. They exhibit cooperative therapeutic effects surpassing those of natural monoclonal antibodies, such as bridging the immune cells and tumor cells to stimulate targeted immune response, or ...
Zhengyang Yuan +4 more
openaire +2 more sources
Critical reviews in immunology, 1993
Bispecific antibodies--molecules combining two different antigenic specificities--are currently being developed as new agents for immunotherapy and for basic studies in cell biology. Bispecific antibodies (BsAb) are prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma ...
M W, Fanger, P M, Morganelli, P M, Guyre
openaire +1 more source
Bispecific antibodies--molecules combining two different antigenic specificities--are currently being developed as new agents for immunotherapy and for basic studies in cell biology. Bispecific antibodies (BsAb) are prepared by chemically linking two different monoclonal antibodies or by fusing two hybridoma cell lines to produce a hybrid-hybridoma ...
M W, Fanger, P M, Morganelli, P M, Guyre
openaire +1 more source
Bispecific antibodies in cancer therapy
Current Opinion in Immunology, 1999Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
D M, Segal, G J, Weiner, L M, Weiner
openaire +2 more sources
Discovery and development of bispecific antibodies
Protein Expression and PurificationBispecific antibodies (BsAbs) represent a significant breakthrough in antibody-based therapeutics, offering the unique capability to engage two distinct targets simultaneously. BsAbs are expected to exert therapeutic effects that are unattainable with conventional antibody drugs. Specifically, they are being developed for use in intercellular bridging,
Tetsuya Wakabayashi, Taichi Kuramochi
openaire +2 more sources
Introduction: bispecific antibodies
Journal of Immunological Methods, 2001D M, Segal, G J, Weiner, L M, Weiner
openaire +2 more sources